Literature DB >> 26997395

Early recurrence of proliferative glomerulonephritis with monoclonal immunoglobulin deposits in a renal allograft.

Rohit Tewari1, Kusum Joshi, Ashwani Kumar, C S Rayat, Rajaram Iyer, Vinay Sakhuja, Mukut Minz.   

Abstract

Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMIDs) is a clinico-pathologic entity, the recurrence of which in the renal allograft has only recently been described. A 55-year-old male presented with rapid deterioration of renal function. Light microscopy showed membranoproliferative glomerulonephritis with kappa light chain restriction and only one sub-class of IgG. He subsequently underwent renal transplant. Two months later, he developed acute graft dysfunction. Renal biopsy showed a recurrence of the disease. Work up for multiple myeloma was positive. Membranoproliferative pattern of injury in the posttransplant setting has a wide range of differential diagnosis, PGNMID being one of them.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26997395     DOI: 10.4103/1319-2442.178568

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  3 in total

Review 1.  Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity.

Authors:  Mariana Ciocchini; Jorge Arbelbide; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2017-04-19       Impact factor: 2.370

2.  A case report of proliferative glomerulonephritis with monoclonal immunoglobulin M-kappa deposits without associated lymphoproliferative disorder or detectable paraproteinemia.

Authors:  Yoshito Yamaguchi; Kunihiko Maeda; Katsuyuki Nagatoya; Atsushi Yamauchi
Journal:  CEN Case Rep       Date:  2017-12-11

Review 3.  The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance.

Authors:  Şadiye Mehtat Ünlü; Hayri Özsan; Sülen Sarıoğlu
Journal:  Turk J Haematol       Date:  2017-08-23       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.